Biotechnology Industry
Filter News
Found 7,295 articles
-
Investors love their takeover rumors, and with biopharma having a good year for mergers and acquisitions, there’s been plenty to keep them busy. Here’s two takeover rumors that came out of Spanish media group Intereconomia.
-
Boston-based PureTech Health inked a multi-year collaboration deal with Swiss-based Roche to advance PureTech’s milk-derived exosome platform technology for oral dosing of Roche’s antisense oligonucleotide platform.
-
Agios Pharmaceuticals Scores FDA Approval For Tibsovo, Second AML Drug Win in Less Than a Year
7/20/2018
Shares of Agios Pharmaceuticals jumped this morning after the company said the FDA approved its oral leukemia treatment Tibsovo (ivosidenib). It’s the second approval for the company in less than a year. -
The Institute for Life Science Entrepreneurship (ILSE) released a white paper highlighting life science incubator space and innovation trends in New Jersey. The report, entitled “Recent Advances in Laboratory and Innovation Space in New Jersey” profiles these efforts.
-
Some diagnostics testing for infectious diseases can be quite invasive and uncomfortable for a patient. Now though, a new form of test is available that can mitigate the need for those invasive tests.
-
July 20 Research Roundup: PARPi and Rare Cancers, “Pleasure” Brain Chemicals and Cancer Suppressi...
7/20/2018
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. -
Sobi™ strengthens inflammation franchise by acquiring global rights for emapalumab from Novimmune
7/20/2018
Swedish Orphan AB, an international biopharmaceutical company dedicated to rare diseases, and NovImmune SA have entered into an exclusive licence agreement for the perpetual global rights to emapalumab, a late-stage orphan drug candidate for the treatment of primary Haemophagocytic lymphohistiocytosis, developed by Novimmune SA, a privately-held, pre-commercial drug discovery and development company focused on rare inflammatory diseases, immune disorders and immuno-oncology.
-
U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi)
7/20/2018
NIVESTYM™, a biosimilar to Neupogen® (filgrastim), is Pfizer’s fourth biosimilar to be approved by the FDA.
-
Highlights from Lilly's Alzheimer's Disease Pipeline at the Alzheimer's Association International Conference® 2018 (AAIC® 2018)
7/20/2018
Eli Lilly and Company (NYSE: LLY) today announced that new results from a number of studies across the company's Alzheimer's disease pipeline will be presented at the Alzheimer's Association International Conference (AAIC) in Chicago, July 22-26, 2018. Nearly 30 oral and poster presentations will underscore Lilly's focus on making a meaningful difference in the lives of people living with Alzheimer's through clinical development and collaboration.
-
PureTech Health Announces Collaboration with Roche to Advance Technology for Oral Administration of Antisense Oligonucleotides
7/20/2018
PureTech Health to receive up to $36 million in upfront payments, research support, and early preclinical milestones and is eligible to potentially receive over $1 billion in development milestones
-
Genentech to Present New Data Demonstrating the Breadth and Depth of Its Alzheimer’s Program at the Upcoming Alzheimer's Association International Conference (AAIC)
7/20/2018
Late-breaking Phase II exploratory analysis of investigational crenezumab to show impact on beta amyloid oligomer levels in cerebral spinal fluid (CSF)
-
Alpine Immune Sciences Completes Sale of S-Nitrosoglutathione Reductase (GSNOR) Assets to Laurel Venture Capital
7/20/2018
Alpine Immune Sciences, Inc., a company focused on discovering and developing innovative, protein-based immunotherapies to treat cancer, autoimmune/inflammatory, and other diseases, and Laurel Venture Capital, a life science focused venture capital fund based in Hangzhou, Zhejiang China, today announced the completion of the sale and transfer of global rights to the S-Nitrosoglutathione Reductase assets from Alpine to Laurel Venture Capital.
-
Sage Bionetworks Launches the Agora Platform Making Curated Genomic Analysis of Alzheimer’s Disease Widely Available
7/20/2018
Sage Bionetworks announces the launch of the Agora platform (agora.ampadportal.org) an interactive, web-based tool that allows researchers to explore curated genomic analyses of Alzheimer’s Disease (AD), including a list of early candidate target nominations for AD.
-
Koutif Therapeutics Confirms Clinical Candidate Drug
7/20/2018
Company Expects to File IND Application in Late 2018.
-
Galapagos and MorphoSys signed an exclusive development and commercialization deal with Swiss-based Novartis.
-
The Chinese biopharma market is booming as more and more companies eye breaking into that rich market. Christophe Weber, chief executive officer of pharma giant Takeda, views its China programs as its second-biggest business behind the United States.
-
Recent studies in early diagnostics underline just how much focus medical technology companies are making on developing different modalities for very early cancer diagnosis. Here are just some recent examples.
-
Roche’s Tecentriq Sees Mixed Results in Interim Phase III Lung Cancer Analysis, Study to Continue
7/19/2018
Roche’s Tecentriq, in combination with chemotherapy, hit its co-primary endpoint of progression-free survival in a Phase III trial for non-small cell lung cancer patients. But, the Swiss pharma giant said the combination has so far failed to achieve statistical significance in overall survival, a... -
Patient Death: Mersana Shares Plunge
7/19/2018
Shares of Mersana Therapeutics have plunged nearly 40 percent this morning after the company announced the FDA placed a partial clinical hold on its Phase I antibody drug conjugate XMT-1522 following the death of a patient. -
In a speech given at the Brookings Institution preceding the release of the U.S. Food and Drug Administration (FDA)’s Biosimilars Action Plan, FDA Commissioner Scott Gottlieb unloaded on big pharma.